YOU GOT THIS

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

20,000+ patients chose LUTATHERA for the opportunity to delay NET progression—join in their strength

Explore how LUTATHERA fits into your NET treatment plan

Actor portrayal.

NET, neuroendocrine tumor.

What is LUTATHERA?

LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults and children aged 12 years and older with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut, and hindgut.

IMPORTANT SAFETY INFORMATION

What are some important things to know about the safety of LUTATHERA?

LUTATHERA is associated with some serious safety considerations and, in some cases, these may require your health care provider to adjust or stop your treatment.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

NOVARTIS

Whether you're considering LUTATHERA or have started treatment, this guide can show you how LUTATHERA can help



LUTATHERA is a NET treatment that works differently than others. It's a targeted radiation treatment called peptide receptor radionuclide therapy (PRRT).

LUTATHERA early can help slow NET progression for longer.

Actor portrayal.

IMPORTANT SAFETY INFORMATION (continued)

What are some important things to know about the safety of LUTATHERA? (continued)

You should always follow your health care provider's instructions. Safety considerations include:

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Where are you in your journey?

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use

3 out of 4 patients with NETs had their tumors get worse over time

Talk to your doctor to find out how LUTATHERA can help slow down your tumor growth.

Actor portrayal.

IMPORTANT SAFETY INFORMATION (continued)

- **Radiation exposure:** Treatment with LUTATHERA will expose you to radiation, which can contribute to your long-term radiation exposure. Overall radiation exposure is associated with an increased risk for cancer.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Some tumors grow faster and need a treatment that can help slow progression

NETs grow and spread over time, also known as progression.

NETs can progress without you knowing—usually, they progress slowly, but some can progress faster and spread quickly.

You can tell how likely NETs are to progress with something called a tumor grade. Your doctor can check the tumor grade with something called a Ki-67 score.

A Ki-67 score tells you how many cells are dividing. The Ki-67 score is a percentage between 0% to 100%. Higher scores mean the cancer is growing quickly and the tumor grade is higher. Lower scores mean the cancer is growing slowly and the tumor grade is lower.

Tumor Grade	1	2	3
Ki-67 Score	Less than 3%	3% to 20%	More than 20%

There are treatment options available to help slow NET growth. One of the first treatments your doctor might talk to you about is somatostatin analogues (SSAs). **If you need more than an SSA to treat your cancer, your doctor could recommend LUTATHERA.**

Regular scans and follow-ups with your doctor can help you see if your cancer is progressing and needs more treatment.

IMPORTANT SAFETY INFORMATION (continued)

- **Radiation exposure (continued):** The radiation will be detectable in your urine for up to 30 days following administration of the drug. It is important to minimize radiation exposure to household contacts consistent with good radiation safety practices as advised by your health care provider.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use

Why is my SSTR status important?

9 out of 10 patients with NETs are SSTR+.

NETs have proteins on the surface of their cells called somatostatin receptors (SSTRs).
If your doctor says you're somatostatin receptor-positive (SSTR+), your tumor has these proteins.

You can find out if your NET is SSTR+ by asking your doctor to schedule an imaging test for SSTR.
LUTATHERA specifically looks for and attacks SSTR+ tumor cells.

Actor portrayals.

IMPORTANT SAFETY INFORMATION (continued)

- **Bone marrow problems:** Treatment with LUTATHERA increases the risk of myelosuppression, a condition in which bone marrow activity is decreased, resulting in a drop in blood cell counts.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

If your NET is SSTR+, could you be ready to start LUTATHERA?

My NET is SSTR+

I'm ready for a **first treatment after my NET diagnosis** and have faster-growing tumors (Ki-67 from 10% to 55%)

— OR —

I'm already **on an SSA** for my NET but my cancer is showing **signs of progression**

You could be ready for

LUTATHERA

Learn more about who is eligible for LUTATHERA

IMPORTANT SAFETY INFORMATION (continued)

- **Bone marrow problems (continued):** You may experience blood-related side effects such as low red blood cells (anemia), low numbers of cells that are responsible for blood clotting (thrombocytopenia), and low numbers of white blood cells (neutropenia).

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

If you're looking for a first treatment after diagnosis, LUTATHERA can help slow NET progression

In a study of 226 patients with faster-growing NETs, LUTATHERA with an SSA was shown to reduce how fast tumors grew or spread **for over a year longer** than SSA treatment alone.

Half of the patients taking LUTATHERA with an SSA did not have their cancer grow or spread for 22.8 months compared with 8.5 months with an SSA alone, roughly 3x more time without their cancer getting worse.



The data are from the NETTER-2 trial, which included 226 patients who were recently diagnosed with SSTR+ NETs that were faster growing (Ki-67, 10%–55%). They were split into 2 groups: 151 received LUTATHERA and a long-acting SSA, and 75 received a long-acting, high-dose SSA alone.

IMPORTANT SAFETY INFORMATION (continued)

- **Bone marrow problems (continued):** Speak with your health care provider if you experience any signs or symptoms of infection, fever, chills, dizziness, shortness of breath, or increased bleeding or bruising. Your health care provider may need to adjust or stop your treatment accordingly.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

With LUTATHERA, 4x more patients also saw their tumors shrink or disappear

More patients with faster-growing NETs saw their tumors shrink or disappear, also known as overall response, with LUTATHERA + SSA compared to SSA alone.



Choosing the first treatment for your cancer is a big step after getting your NET diagnosis. Talk to your doctor about starting treatment with LUTATHERA

IMPORTANT SAFETY INFORMATION (continued)

- **Secondary bone marrow and blood cancers:** Other serious conditions that you may develop as a direct result of treatment with LUTATHERA include blood and bone marrow disorders known as secondary myelodysplastic syndrome and cancer known as acute leukemia.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

If your NETs have progressed on an SSA, LUTATHERA can delay NET progression for longer

In a study of 229 patients whose NETs progressed on an SSA alone, LUTATHERA + SSA helped delay tumors from growing or spreading by **more than 2 years.**

LUTATHERA + SSA gave patients more time without their cancer growing or spreading: 28.4 months compared with 8.5 months with an SSA alone, or more than 2 years without their cancer getting worse.

The data are from the NETTER-1 trial, which included 229 patients with SSTR+ NETs who had tumors that were slower growing (Ki-67, 0%–20%) and progressed on treatment with an SSA. They were split into 2 groups: 116 received LUTATHERA and a long-acting SSA, and 113 received a long-acting, high-dose SSA alone.

IMPORTANT SAFETY INFORMATION (continued)

- **Secondary bone marrow and blood cancers (continued):** Your health care provider will routinely check your blood cell counts and tell you if they are too low or too high.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

3x more patients who had SSA treatment before saw their tumor shrink or disappear with LUTATHERA

More patients whose NETs had progressed on an SSA alone saw their tumors shrink or disappear, also known as overall response, with LUTATHERA + SSA compared to those taking an SSA alone.



If your NET has progressed after taking an SSA alone, talk to your doctor today about adding LUTATHERA to your treatment plan

IMPORTANT SAFETY INFORMATION (continued)

- **Kidney problems:** Treatment with LUTATHERA will expose your kidneys to radiation and may impair their ability to work as normal. You may be at an increased risk for kidney problems after LUTATHERA treatment if you already have kidney impairment before treatment.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

LUTATHERA may be right for you

whether you have or have not had prior treatment for NETs

Ask your doctor if LUTATHERA is the right option for you right now.

Some questions to start the conversation:

1. Where is my cancer located?

2. What grade are my NETs?

3. Is my cancer SSTR+?

4. How fast is my cancer growing/progressing?

Actor portrayal.

IMPORTANT SAFETY INFORMATION (continued)

- **Kidney problems (continued):** In some cases, patients have experienced kidney failure after treatment with LUTATHERA. Your health care provider will provide you with an amino acid solution before, during, and after LUTATHERA to help protect your kidneys. You should stay well hydrated before, on the day of, and on the day after your treatment.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Understanding side effects with LUTATHERA

All prescription medications have side effects you need to think about. It's natural to want to know about the potential side effects before starting treatment. Ask your care team if you have any questions or want more information.

What are the most common side effects for LUTATHERA?

In clinical trials, the most common and most serious side effects of LUTATHERA include:

- Decreased blood cell counts
- Increased liver enzymes
- Vomiting
- Nausea
- Increased blood glucose
- Decreased blood potassium levels

Some side effects you should know about before starting LUTATHERA include:

- Radiation exposure
- Bone marrow problems
- Secondary bone marrow and blood cancers
- Kidney problems
- Liver problems
- Allergic reactions
- Hormonal gland problems (carcinoid crisis)
- Embryo-fetal toxicity
- Infertility

There are other possible side effects of LUTATHERA. Talk to your care team if you experience any side effects. You are encouraged to report negative side effects of prescription drugs to the FDA.

Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

IMPORTANT SAFETY INFORMATION (continued)

- **Kidney problems (continued):** You should urinate frequently before, on the day of, and on the day after administration of LUTATHERA. Your doctor will monitor your kidney function and may withhold, reduce, or stop your LUTATHERA treatment accordingly.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

What happens if I have side effects?

Your care team will monitor you for side effects during your treatment. This includes doing blood work or other tests. If you experience side effects, there are many ways your care team can help, including:

- Giving you medicine to help with side effects (for example, treatment to protect your kidneys)
- Delaying your LUTATHERA treatment
- Changing the dose of LUTATHERA
- Stopping LUTATHERA treatment if needed



Actor portrayal.

IMPORTANT SAFETY INFORMATION (continued)

- **Liver problems:** In clinical studies of LUTATHERA, less than 1% of patients were reported to have tumor bleeding (hemorrhage), swelling (edema), or tissue damage (necrosis) to the liver.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

How will I receive LUTATHERA?

Your doctor will send you to a treatment center that is trained specifically to give LUTATHERA.

LUTATHERA is given in 4 intravenous (IV) treatments, once every 8 weeks



Between **4 to 24 hours after each dose** of LUTATHERA, you'll get an intramuscular (IM) injection of **long-acting SSA.**

After your last dose of LUTATHERA, you may continue receiving long-acting SSA every 4 weeks for **up to 18 months.**

> ***You and your doctor will work together to decide on the best dosing plan for your cancer***

IMPORTANT SAFETY INFORMATION (continued)

- **Liver problems (continued):** If you have tumors in your liver, you may be more likely to experience these side effects. Tell your health care provider right away if you have any of these signs and symptoms of liver problems: yellowing of the skin or the whites of the eyes (jaundice), unusual darkening of the urine, unusual tiredness, right upper stomach area (abdomen) pain, confusion, and/or swelling of the stomach area (abdomen). Your health care provider will monitor your liver using blood tests and may need to withhold, reduce, or stop your LUTATHERA treatment accordingly.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

There are over 440 LUTATHERA treatment sites across the United States. Find one near you

Actor portrayal.

IMPORTANT SAFETY INFORMATION (continued)

- **Allergic reactions:** Allergic reactions have occurred in people who were treated with LUTATHERA. Notify your health care provider if you develop symptoms of an allergic reaction.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

What should I know about targeted radiation?

It's understandable to have questions about the targeted radiation LUTATHERA delivers. Learning how it works in your body can help you feel more informed about the treatment.

The radiation travels no more than 2.2 millimeters

Beta radiation from the LUTATHERA infusion spreads no more than 2.2 millimeters (about 1/10 of an inch) in your tissue. This **is similar to the thickness of a nickel coin.**

The amount of radiation exposure to those around you is less than a chest x-ray

In a clinical trial, the average total exposure to caregivers in the 5 days after a treatment was **less than the exposure from 1 chest x-ray.**

Radiation from LUTATHERA will not stay in your body long

Within 2 days, most of the radiation will leave your body.

Within 2 weeks, more than 99% of radiation will be gone.

> ***You will have to wait until the amount of radiation in your body decreases before you can leave the treatment center. After each infusion, your care team will monitor the radiation in your body and tell you when it is safe to leave***

IMPORTANT SAFETY INFORMATION (continued)

- **Allergic reactions (continued):** Seek emergency help right away for any serious allergic reactions. Symptoms may include trouble breathing or swallowing; raised bumps (hives); rash or itching; and swelling of the face, lips, tongue, throat, or arms.
- **Hormonal gland problems (carcinoid crisis):** During your treatment you may experience certain symptoms that are related to hormones released from your cancer. These symptoms may include flushing, diarrhea, difficulty breathing (bronchospasm), and may occur during or within the 24 hours after your first LUTATHERA treatment. Your health care provider will monitor you closely. Speak with your health care provider if you experience any of these signs or symptoms.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Help reduce radiation exposure after treatment

Your body, blood, and urine give off radiation for a period of time after getting LUTATHERA. It's important to follow these instructions and any others from your doctor.

Stay hydrated

- Drink plenty of fluids the day before, the day of, and the day after treatment to help get rid of any extra radiation

Shower daily

- Shower daily after treatment

Maintain distance after treatment and separate belongings*

- Separate your belongings
- Stay at least 3 feet from your loved ones (and pets)
- Sleep in a separate bedroom and avoid sex for 3 days

Stay seated on the toilet

- Use the toilet in a seated position and flush twice for at least 3 days after your LUTATHERA dose
- Your loved ones should use gloves when providing bathroom assistance

Separate your clothing/laundry

- At the treatment center, change into hospital scrubs/gowns
- At home, use separate towels and washcloths and wash your clothing separately for at least 3 days after treatment

Throw away waste

- Flush or throw away items that have been exposed to bodily fluids
- Separate contaminated waste from household waste

*Ask your doctor or radiation technologist for more information.

IMPORTANT SAFETY INFORMATION (continued)

- **Pregnancy warning:** Tell your health care provider if you are pregnant.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use

What should I expect before each dose of LUTATHERA?

4 WEEKS OR MORE BEFORE TREATMENT

- Your doctor will stop your long-acting SSA treatment until your first LUTATHERA dose
- You may receive a short-acting SSA to help with symptoms before you start LUTATHERA

24 HOURS OR MORE BEFORE TREATMENT

- Your doctor will stop short-acting SSA treatment at least 24 hours before each infusion

Learn more about what your LUTATHERA treatment could look like

IMPORTANT SAFETY INFORMATION (continued)

- **Pregnancy warning (continued):** LUTATHERA can harm your unborn baby. Females should use an effective method of birth control during treatment and for 7 months after the last dose of LUTATHERA.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use

What should I expect on infusion day?

BEFORE RECEIVING YOUR INFUSION AT THE TREATMENT CENTER

- You will be given a medicine to help with any nausea and vomiting that you may experience
- Thirty minutes before you are given LUTATHERA, you will start an amino acid infusion. This will help protect your kidneys

GETTING YOUR LUTATHERA INFUSION

- The total infusion time is ~4 to 5 hours
  - LUTATHERA infusion takes 30 to 40 minutes
  - You will continue the amino acid infusion for at least 3 hours after the LUTATHERA infusion to protect your kidneys
  - Your care team will monitor you throughout the day

What does follow-up after my infusion look like?

4 TO 24 HOURS AFTER INFUSION

- Your care team will tell you when and where you will receive a long-acting SSA

LAB TESTS

- Your care team will do regular blood work and other tests to see how you are doing on treatment
- These tests can tell them if you are having side effects and will help them give you the care you need

IMPORTANT SAFETY INFORMATION (continued)

- **Pregnancy warning (continued):** Males with female partners should use an effective method of birth control during treatment with LUTATHERA and for 4 months after the last dose.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use

Novartis Patient Support™

LUTATHERA is an infusion given at your nearest treatment center

Because LUTATHERA uses radiation, your doctor will send you to a treatment center that is trained to give LUTATHERA.

Navigate the insurance process

Your dedicated Novartis Patient Support team will work with your provider to help navigate insurance coverage for LUTATHERA.

Get financial support*

If you have private insurance, you could be eligible for Co-Pay and pay as little as $0 for your LUTATHERA treatment.

Answer questions across the treatment journey

Live 1-on-1 support is available for patients starting treatment. Our Patient Navigators can help answer the most common treatment questions.

If you have already been prescribed LUTATHERA, sign up for Novartis Patient Support

Call 1-844-638-7222,
Monday through Friday, 8 AM to 8 PM ET, excluding holidays.

Ask your health care provider to help you sign up for assistance, like the Co-Pay Plus offer.

***Limitations apply.** Up to $15,000 over the course of the treatment. Offer not valid under Medicare, Medicaid, or any other federal or state programs. Novartis reserves the right to rescind, revoke, or amend this program without notice. Additional limitations may apply. See complete Terms & Conditions at lutathera.com/copay-terms for details.

IMPORTANT SAFETY INFORMATION (continued)

- **Breastfeeding warning:** You should not breastfeed during treatment with LUTATHERA and for 2.5 months after your last dose of LUTATHERA.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Meet Donna, one of the 20,000+ patients who chose treatment with LUTATHERA

"My local oncologist had suggested LUTATHERA as an option to slow the progression. This was the best long-term option for me and my disease burden at the time."

Actual patient.

Watch how Donna, an actual patient, took control of her NET journey with LUTATHERA

IMPORTANT SAFETY INFORMATION (continued)

- **Fertility problems:** Treatment with LUTATHERA may cause infertility.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Find my NET community

Cancer Support Community (CSC)
5614 Connecticut Avenue, NW Suite 280
Washington, DC 20015
888-793-9355
www.cancersupportcommunity.org

Northern California CarciNET Community (NorCal CarciNET)
484 Lake Park Ave, # 676
Oakland, CA 94610
info@norcalcarcinet.org
www.norcalcarcinet.org

Neuroendocrine Tumor Research Foundation (NETRF)
100 Hancock Street, Third floor
Quincy, MA 02171
1-617-946-1780
info@netrf.org
www.netrf.org

The Neuroendocrine Cancer Awareness Network (NCAN)
3074 Brookchase Boulevard
Fort Mill, SC 29707
1-866-850-9555
info@netcancerawareness.org
www.netcancerawareness.org

The Healing NET Foundation
415 Spence Lane
Nashville, TN 37210
1-615-369-6463
info@thehealingnet.org
www.thehealingnet.org

Neuroendocrine Cancer Foundation (NCF)
PO Box 370466
Denver, CO 80237
info@ncf.net
www.ncf.net

Provided for informational purposes only. This is not intended to be a recommendation or endorsement of any organization. The organizations and websites listed are maintained by third parties over which Novartis Pharmaceuticals Corporation has no control. As such, Novartis Pharmaceuticals Corporation makes no representation as to the accuracy or any other aspect of the information supplied by these organizations or contained in these websites.
The aforementioned organization names and logos are trademarks of their respective owners and are used with permission.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use

Important words to know

Amino acid infusion: an infusion of protein building blocks to help protect the kidneys during radiation treatment

Beta radiation: a type of radiation shown to kill cancer cells

Gastroenteropancreatic neuroendocrine tumor (GEP-NET): a type of cancer that comes from the neuroendocrine cells of the gastrointestinal tract (such as the stomach, small intestine, colon, rectum, appendix) or the pancreas

Grade: how normal or abnormal cancer cells look under a microscope. The more abnormal a cancer cell looks, the more aggressive it is and the higher the grade

Hormone: a chemical produced in the body that travels through your bloodstream to help regulate body functions

Intramuscular (IM): an injection into a muscle

Ki-67: a protein in actively dividing cells, used to assess the rate of cell growth and determine tumor grade

Kidneys: organs that filter waste from the body

Lymph nodes: bean-shaped tissues that filter fluid in your body for harmful substances or cells

Neuroendocrine cells: cells that regulate body function through hormones and other messengers

Neuroendocrine tumor (NET): a tumor that comes from cells that release hormones into the blood in response to a signal from the nervous system

Overall response rate (ORR): the percentage of patients whose cancer got smaller or disappeared in response to treatment

Pancreas: a gland behind your stomach that releases enzymes which help with digestion and hormones to regulate blood sugar

Peptide receptor radionuclide therapy (PRRT): a type of radiation treatment that specifically targets neuroendocrine tumors by binding to proteins on the surface of tumor cells and destroying them

Progression: when cancer becomes worse or spreads throughout the body

Progression-free survival (PFS): a measure of the amount of time during and after treatment that a patient lives without their cancer progressing

Somatostatin analogue (SSA): a man-made drug that mimics the natural hormone somatostatin

Somatostatin receptor (SSTR): a protein on the surface of cells that binds to a hormone called somatostatin, which helps control the release of other hormones

SSTR imaging: a scan your doctor will run to see if your cancer cells have SSTRs. You may have heard this referred to as a gallium/copper positron emission tomography (PET) scan

Stage: how large a cancer is and how far it has spread to other parts of the body

Targeted radiation: treatment that uses radiation to precisely destroy cancer cells while minimizing damage to healthy cells

What is LUTATHERA?

LUTATHERA® (lutetium Lu 177 dotatate) is a prescription medicine used to treat adults and children aged 12 years and older with a type of cancer known as gastroenteropancreatic neuroendocrine tumors (GEP-NETs) that are positive for the hormone receptor somatostatin, including GEP-NETs in the foregut, midgut, and hindgut.

IMPORTANT SAFETY INFORMATION

What are some important things to know about the safety of LUTATHERA?

LUTATHERA is associated with some serious safety considerations and, in some cases, these may require your health care provider to adjust or stop your treatment. You should always follow your health care provider's instructions. Safety considerations include:

- **Radiation exposure:** Treatment with LUTATHERA will expose you to radiation, which can contribute to your long-term radiation exposure. Overall radiation exposure is associated with an increased risk for cancer. The radiation will be detectable in your urine for up to 30 days following administration of the drug. It is important to minimize radiation exposure to household contacts consistent with good radiation safety practices as advised by your health care provider.
- **Bone marrow problems:** Treatment with LUTATHERA increases the risk of myelosuppression, a condition in which bone marrow activity is decreased, resulting in a drop in blood cell counts. You may experience blood-related side effects such as low red blood cells (anemia), low numbers of cells that are responsible for blood clotting (thrombocytopenia), and low numbers of white blood cells (neutropenia). Speak with your health care provider if you experience any signs or symptoms of infection, fever, chills, dizziness, shortness of breath, or increased bleeding or bruising. Your health care provider may need to adjust or stop your treatment accordingly.
- **Secondary bone marrow and blood cancers:** Other serious conditions that you may develop as a direct result of treatment with LUTATHERA include blood and bone marrow disorders known as secondary myelodysplastic syndrome and cancer known as acute leukemia. Your health care provider will routinely check your blood cell counts and tell you if they are too low or too high.
- **Kidney problems:** Treatment with LUTATHERA will expose your kidneys to radiation and may impair their ability to work as normal. You may be at an increased risk for kidney problems after LUTATHERA treatment if you already have kidney impairment before treatment. In some cases, patients have experienced kidney failure after treatment with LUTATHERA. Your health care provider will provide you with an amino acid solution before, during, and after LUTATHERA to help protect your kidneys. You should stay well hydrated before, on the day of, and on the day after your treatment. You should urinate frequently before, on the day of, and on the day after administration of LUTATHERA. Your doctor will monitor your kidney function and may withhold, reduce, or stop your LUTATHERA treatment accordingly.
- **Liver problems:** In clinical studies of LUTATHERA, less than 1% of patients were reported to have tumor bleeding (hemorrhage), swelling (edema), or tissue damage (necrosis) to the liver. If you have tumors in your liver, you may be more likely to experience these side effects. Tell your health care provider right away if you have any of these signs and symptoms of liver problems: yellowing of the skin or the whites of the eyes (jaundice), unusual darkening of the urine, unusual tiredness, right upper stomach area (abdomen) pain, confusion, and/or swelling of the stomach area (abdomen). Your health care provider will monitor your liver using blood tests and may need to withhold, reduce, or stop your LUTATHERA treatment accordingly.

Please see additional Important Safety Information throughout and full Prescribing Information for LUTATHERA.

LUTATHERA® (lutetium Lu 177 dotatate) injection, for intravenous use

- **Allergic reactions:** Allergic reactions have occurred in people who were treated with LUTATHERA. Notify your health care provider if you develop symptoms of an allergic reaction. Seek emergency help right away for any serious allergic reactions. Symptoms may include trouble breathing or swallowing; raised bumps (hives); rash or itching; and swelling of the face, lips, tongue, throat, or arms.
- **Hormonal gland problems (carcinoid crisis):** During your treatment you may experience certain symptoms that are related to hormones released from your cancer. These symptoms may include flushing, diarrhea, difficulty breathing (bronchospasm), and low blood pressure (hypotension), and may occur during or within the 24 hours after your first LUTATHERA treatment. Your health care provider will monitor you closely. Speak with your health care provider if you experience any of these signs or symptoms.
- **Pregnancy warning:** Tell your health care provider if you are pregnant. LUTATHERA can harm your unborn baby. Females should use an effective method of birth control during treatment and for 7 months after the last dose of LUTATHERA. Males with female partners should use an effective method of birth control during treatment with LUTATHERA and for 4 months after the last dose.
- **Breastfeeding warning:** You should not breastfeed during treatment with LUTATHERA and for 2.5 months after your last dose of LUTATHERA.
- **Fertility problems:** Treatment with LUTATHERA may cause infertility. This is because radiation absorbed by your testes or ovaries over the treatment period falls within the range of exposure in which temporary or permanent infertility may occur.

What are the most common side effects of LUTATHERA?

The most common and most serious side effects of LUTATHERA include decreased blood cell counts, increased liver enzymes, vomiting, nausea, increased blood glucose, and decreased blood potassium levels.

Talk to your doctor if you experience any of these side effects. There are other possible side effects of LUTATHERA. For more information and to learn more about LUTATHERA, talk to your doctor or health care provider.

Adverse reactions observed in children aged 12 years and older were similar to those observed in adults treated with LUTATHERA.

What other medicines may interact with LUTATHERA?

Tell your health care provider if you are taking any other medications. You should stop taking your long-acting somatostatin analogue at least 4 weeks before LUTATHERA treatment. You may continue taking short-acting somatostatin analogues up to 24 hours before your LUTATHERA treatment.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

Please see full Prescribing Information for LUTATHERA.

YOU GOT THIS

20,000+ patients chose LUTATHERA for the opportunity to delay NET progression—join in their strength

Visit LUTATHERA.com to learn more

Actor portrayal.

IMPORTANT SAFETY INFORMATION (continued)

- **Fertility problems (continued):** This is because radiation absorbed by your testes or ovaries over the treatment period falls within the range of exposure in which temporary or permanent infertility may occur.

NOVARTIS

LUTATHERA®
(lutetium Lu 177 dotatate)
injection, for intravenous use

Novartis Pharmaceuticals Corporation
East Hanover, New Jersey 07936-1080

3/26 FA-11603657